These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process. Escrieut C, Gigoux V, Archer E, Verrier S, Maigret B, Behrendt R, Moroder L, Bignon E, Silvente-Poirot S, Pradayrol L, Fourmy D. J Biol Chem; 2002 Mar 01; 277(9):7546-55. PubMed ID: 11724786 [Abstract] [Full Text] [Related]
6. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies. Bignon E, Bachy A, Boigegrain R, Brodin R, Cottineau M, Gully D, Herbert JM, Keane P, Labie C, Molimard JC, Olliero D, Oury-Donat F, Petereau C, Prabonnaud V, Rockstroh MP, Schaeffer P, Servant O, Thurneyssen O, Soubrié P, Pascal M, Maffrand JP, Le Fur G. J Pharmacol Exp Ther; 1999 May 01; 289(2):742-51. PubMed ID: 10215648 [Abstract] [Full Text] [Related]
7. Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists. Bläker M, Ren Y, Gordon MC, Hsu JE, Beinborn M, Kopin AS. Mol Pharmacol; 1998 Nov 01; 54(5):857-63. PubMed ID: 9804620 [Abstract] [Full Text] [Related]
8. Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex. Harper EA, Griffin EP, Shankley NP, Black JW. Br J Pharmacol; 1999 Mar 01; 126(6):1496-503. PubMed ID: 10217545 [Abstract] [Full Text] [Related]
9. Are radioligand antagonist/agonist binding ratios in rat pancreas predictive of functional efficacy of cholecystokinin receptor agonists and antagonists? Patel S, Chapman KL, Smith AJ, Bailey I, Freedman SB. Regul Pept; 1996 Aug 27; 65(1):29-35. PubMed ID: 8876033 [Abstract] [Full Text] [Related]
13. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. Gully D, Fréhel D, Marcy C, Spinazzé A, Lespy L, Neliat G, Maffrand JP, Le Fur G. Eur J Pharmacol; 1993 Feb 23; 232(1):13-9. PubMed ID: 7681406 [Abstract] [Full Text] [Related]
14. Effects of the CCK(A) receptor antagonists SR 27897B and PD140548 on baroreflex function in conscious rats. Bunting MW, Beart PM, Widdop RE. Eur J Pharmacol; 1997 Oct 15; 337(1):35-9. PubMed ID: 9389378 [Abstract] [Full Text] [Related]
15. Characterisation of the effects of SR146131, a novel non-peptide CCK(1) receptor agonist, on IMR-32 human neuroblastoma cells. Schaeffer P, Nestor AL, Prabonnaud V, Bachy A, Laplace MC, Keane PE, Bignon E, Herbert JM. Eur J Pharmacol; 2000 Jun 02; 397(2-3):303-10. PubMed ID: 10844128 [Abstract] [Full Text] [Related]
16. Mutational analysis of the putative devazepide binding site of the CCK(A) receptor. Smeets RL, IJzerman AP, Hermsen HP, Ophorst OJ, Van Emst-de Vries SE, De Pont JJ, Willems PH. Eur J Pharmacol; 1997 Apr 23; 325(1):93-9. PubMed ID: 9151944 [Abstract] [Full Text] [Related]
17. Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Silvente-Poirot S, Escrieut C, Wank SA. Mol Pharmacol; 1998 Aug 23; 54(2):364-71. PubMed ID: 9687578 [Abstract] [Full Text] [Related]
18. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702. Durieux C, Ruiz-Gayo M, Corringer PJ, Bergeron F, Ducos B, Roques BP. Mol Pharmacol; 1992 Jun 23; 41(6):1089-95. PubMed ID: 1614411 [Abstract] [Full Text] [Related]